All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld MedTech Perspectives » Why Canada?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Diagnostics

Why Canada?

Nov. 22, 2011
By Amanda Pedersen
No Comments

Earlier this year GE Healthcare established its first global Pathology Imaging Centre of Excellence (PICE) in Toronto, Ontario.

GE and its digital pathology joint venture, Omnyx, will invest $7.75 million along with a $2.25 million grant from the Health Technology Commercialization Program created by Ontario’s Health Technology Exchange and funded by the Ontario Ministry of Research and Innovation. Planned collaborative R&D partnerships are expected to bring an additional $7.2 million, for a total investment of $17.2 million over the next three years.

Considering GE is a massive global corporation with locations all over the world and its JV Omnyx is based in Pittsburgh, it’s only natural to ask: Why Canada?

“Why Canada? It’s GE – we could have put it on the moon if we tried,” Luigi Gentile, executive director of GE’s PICE told Medical Device Daily and about 14 other journalists participating in Ontario’s advanced medical devices media tour. Gentile listed several factors that supported the company’s choice to make Toronto the home for its new pathology center. Some of those factors include: the high quality of pathology that happens in Canada; the experience and early adoption that the country has had in digital pathology; great pool of experts in both molecular and digital anatomical pathology; and the fact that the large geographic area of Canada creates an opportunity to develop a model in Canada that is very exportable to countries like Brazil, Russia, India, and China that are all facing the same challenges.

And of course the money that the Canadian and Ontario governments kicked in for the center may have influenced the decision a bit too. More than just providing funding, the government has brought together all the partners of industry, government, and clinicians to one central location in Toronto’s MaRS Discovery District.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing